One year ago, on March 1, 2025, Metanova Labs launched NOVA, their flagship project on Bittensor’s Subnet 68 (SN68). This marked the beginning of a revolutionary approach to AI-driven drug discovery, blending biotechnology with decentralized incentives to tackle longstanding challenges in the pharmaceutical industry.
As a crypto-native biotech company, Metanova is focused on developing next-generation therapeutics that reprogram the body and mind, addressing mental health and other conditions through innovative, merit-based competition powered by the Bittensor network.
NOVA abstracts drug discovery into a decentralized compute economy. Miners on the network submit algorithms to explore ultra-large chemical spaces, screening billions of synthesizable molecules for potential therapeutic uses. This method dramatically accelerates the process while reducing costs, bypassing traditional bottlenecks like high expenses and gatekeeping in in vitro methods.
The past year has been a testament to NOVA’s potential, with impressive milestones that prove the viability of this decentralized model. Metanova explored 65 billion chemical possibilities through 5 combinatorial reactions, identifying over 11 million molecules and probing 30,000 proteins. The team developed 4.5 unique algorithms, fine-tuned 2 models, and explored 9 drug targets across 2 therapeutic modalities. Engineering efforts included 581 commits, while outreach saw 12 podcasts and articles, plus 2 signed partnerships.
These achievements highlight the project’s rapid growth and community-driven progress. Looking ahead, Year 2 promises even greater impact. The team’s focus will shift to “closing the loop” and deploying a relentless discovery engine into real-world applications.
In a space plagued by inefficiencies, Metanova Labs stands out as a beacon of innovation, proving that decentralized AI can cure not just diseases, but the broken systems behind drug development.
The best, indeed, is yet to come.
Be the first to comment